Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line

Molecular Pharmacology

Volumn 80, Issue 3, 2011, Pages 518-528

  Hasegawa, Maki ^a   Kapelyukh, Yury ^b   Tahara, Harunobu ^a   Seibler, Jost ^d   Rode, Anja ^d   Krueger, Sylvia ^d   Lee, Dongtao N ^b   Wolf, C Roland ^b,c   Scheer, Nico ^d  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b CXR Biosciences Ltd   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d TaconicArtemis GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; PIOGLITAZONE; PREGNANE X RECEPTOR; RIFAMPICIN; SULFINPYRAZONE; TRIAZOLAM;

ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; LIVER; MALE; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

ANIMALS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, STEROID;

EID: 80052011288     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.071845     Document Type: Article

References (47)

1. Anakk S., Kalsotra A., Kikuta Y., Huang W., Zhang J., Staudinger J.L., Moore DD, and Strobel H.W. (2004) CAR/PXR provide directives for Cyp3a41 gene regulation differently from Cyp3a11. Pharmacogenomics J 4:91-101. (Pubitemid 38499992)
2. Backman J.T., Olkkola KT, and Neuvonen P.J. (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13. (Pubitemid 26046768)
3. Bradbrook I.D., John V.A., Morrison P.J., Rogers HJ, and Spector R.G. (1982) Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. Br J Clin Pharmacol 13:177-185. (Pubitemid 13143950)
4. Budde K., Neumayer H.H., Fritsche L., Sulowicz W., Stompôr T, and Eckland D. (2003) The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368-374. (Pubitemid 36535367)
5. Burk O., Tegude H., Koch I., Hustert E., Wolbold R., Glaeser H., Klein K., Fromm M.F., Nuessler A.K., Neuhaus P., et al. (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:24280-24288. (Pubitemid 34951946)
6. Caforio A.L., Gambino A., Tona F., Feltrin G., Marchini F., Pompei E., Testolin L., Angelini A., Dalla Volta S, and Casarotto D. (2000) Sulfinpyrazone reduces cyclosporine levels: A new drug interaction in heart transplant recipients. J Heart Lung Transplant 19:1205-1208.
7. Cheung C and Gonzalez F.J. (2008) Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327:288-299.
8. Chung E., Nafziger A.N., Kazierad DJ, and Bertino J.S., Jr. (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79:350-361.
9. Dai D., Bai R., Hodgson E, and Rose R.L. (2001) Cloning, sequencing, heterologous expression, and characterization of murine cytochrome P450 3a25*(Cyp3a25), a testosterone 6beta-hydroxylase. J Biochem Mol Toxicol 15:90-99. (Pubitemid 32322057)
10. De Wildt S.N., Kearns G.L., Leeder JS, and Van den Anker J.N. (1999) Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 37:485-505. (Pubitemid 30032252)
11. Fahmi O.A., Hurst S., Plowchalk D., Cook J., Guo F., Youdim K., Dickins M., Phipps A., Darekar A., Hyland R., et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
12. Forrester L.M., Neal G.E., Judah D.J., Glancey MJ, and Wolf C.R. (1990) Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc Natl Acad Sci USA 87:8306-8310.
13. Granvil C.P., Yu A.M., Elizondo G., Akiyama T.E., Cheung C., Feigenbaum L., Krausz KW, and Gonzalez F.J. (2003) Expression of the human CYP3A4 gene in the small intestine of transgenic mice: In vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548-558. (Pubitemid 36444163)
14. Hebert M.F., Roberts J.P., Prueksaritanont T, and Benet L.Z. (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
15. Hogan B.L., Beddington R.S., Costantini F, and Lacy E. (1994) Production of transgenic mice, in Manipulating the Mouse Embryo: A Laboratory Manual, pp 253-289, Cold Spring Harbor Laboratory Press, Plainview, NY.
16. Itoh S., Satoh M., Abe Y., Hashimoto H., Yanagimoto T, and Kamataki T. (1994) A novel form of mouse cytochrome P450 3A (Cyp3a-16). Its cDNA cloning and expression in fetal liver. Eur J Biochem 226:877-882.
17. Kim S., Dinchuk J.E., Anthony M.N., Orcutt T., Zoeckler M.E., Sauer M.B., Mosure K.W., Vuppugalla R., Grace J.E. Jr, Simmermacher J., et al. (2010) Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction. Drug Metab Dispos 38:16-24.
18. Kim S., Pray D., Zheng M., Morgan D.G., Pizzano J.G., Zoeckler M.E., Chimalakonda A, and Sinz M.W. (2008) Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: Extrapolation to human CYP3A4 induction potential. Drug Metab Lett 2:169-175.
19. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391. (Pubitemid 32268418)
20. Kyrklund C., Backman J.T., Kivistö K.T., Neuvonen M., Laitila J, and Neuvonen P.J. (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68:592-597. (Pubitemid 32059984)
21. Lee G and Saito I. (1998) Role of nucleotide sequences of loxP spacer region in Cre-mediated recombination. Gene 216:55-65. (Pubitemid 28389102)
22. Ma X., Cheung C., Krausz K.W., Shah Y.M., Wang T., Idle JR, and Gonzalez F.J. (2008) A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 36:2506-2512.
23. Ma X., Shah Y., Cheung C., Guo G.L., Feigenbaum L., Krausz K.W., Idle JR, and Gonzalez F.J. (2007) The PREgnane X receptor gene-humanized mouse: A model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35:194-200. (Pubitemid 46148730)
24. Moore L.B., Parks D.J., Jones S.A., Bledsoe R.K., Consler T.G., Stimmel J.B., Goodwin B., Liddle C., Blanchard S.G., Willson T.M., et al. (2000) Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:15122-15127. (Pubitemid 30337234)
25. Nebert DW and Russell D.W. (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162. (Pubitemid 35246494)
26. Nelson D.R., Zeldin D.C., Hoffman S.M., Maltais L.J., Wain HM, and Nebert D.W. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18. (Pubitemid 38183957)
27. Pascussi J.M., Jounaidi Y., Drocourt L., Domergue J., Balabaud C., Maurel P, and Vilarem M.J. (1999) Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem Biophys Res Commun 260:377-381. (Pubitemid 29352073)
28. Polk R.E., Brophy D.F., Israel D.S., Patron R., Sadler B.M., Chittick G.E., Symonds W.T., Lou Y., Kristoff D, and Stein D.S. (2001) Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 45:502-508. (Pubitemid 32105287)
29. Prueksaritanont T., Vega J.M., Zhao J., Gagliano K., Kuznetsova O., Musser B., Amin R.D., Liu L., Roadcap B.A., Dilzer S., et al. (2001) Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 41:573-581. (Pubitemid 32381875)
30. Ripp S.L., Mills J.B., Fahmi O.A., Trevena K.A., Liras J.L., Maurer TS, and De Morais S.M. (2006) Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 34:1742-1748. (Pubitemid 44427477)
31. Sahi J., Black C.B., Hamilton G.A., Zheng X., Jolley S., Rose K.A., Gilbert D., LeCluyse EL, and Sinz M.W. (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439-446. (Pubitemid 36378521)
32. Sakuma T., Takai M., Endo Y., Kuroiwa M., Ohara A., Jarukamjorn K., Honma R, and Nemoto N. (2000) A novel female-specific member of the CYP3A gene subfamily in the mouse liver. Arch Biochem Biophys 377:153-162. (Pubitemid 30257300)
33. Scheer N., Ross J., Kapelyukh Y., Rode A, and Wolf C.R. (2010) In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. Drug Metab Dispos 38:1046-1053.
34. Scheer N., Ross J., Rode A., Zevnik B., Niehaves S., Faust N, and Wolf C.R. (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228-3239.
35. Schlicht F., Staiger C., De Vries J., Gundert-Remy U., Hildebrandt R., Harenberg J., Wang NS, and Weber E. (1985) Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. Eur J Clin Pharmacol 28:97-103. (Pubitemid 15126535)
36. Sinz M., Kim S., Zhu Z., Chen T., Anthony M., Dickinson K, and Rodrigues A.D. (2006) Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375-388.
37. Stanley L.A., Horsburgh B.C., Ross J., Scheer N, and Wolf C.R. (2006) PXR and CAR: Nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38:515-597. (Pubitemid 44167200)
38. Stevens J.C., Hines R.N., Gu C., Koukouritaki S.B., Manro J.R., Tandler PJ, and Zaya M.J. (2003) Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307:573-582. (Pubitemid 37310671)
39. Tornio A., Niemi M., Neuvonen PJ, and Backman J.T. (2008) Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 36:73-80.
40. Van Herwaarden A.E., Wagenaar E., Van der Kruijssen C.M., Van Waterschoot R.A., Smit J.W., Song J.Y., Van der Valk M.A., Van Tellingen O., Van der Hoorn J.W., Rosing H., et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. (Pubitemid 350097013)
41. Villikka K., Kivistö K.T., Backman J.T., Olkkola KT, and Neuvonen P.J. (1997) Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 61:8-14. (Pubitemid 27072879)
42. Wallace H.A., Marques-Kranc F., Richardson M., Luna-Crespo F., Sharpe J.A., Hughes J., Wood W.G., Higgs DR, and Smith A.J. (2007) Manipulating the mouse genome to engineer precise functional syntenic replacements with human sequence. Cell 128:197-209. (Pubitemid 46048892)
43. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., Hamman M.A., Hall SD, and Wrighton S.A. (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30:883-891. (Pubitemid 34815417)
44. Xie W., Barwick J.L., Downes M., Blumberg B., Simon C.M., Nelson M.C., Neuschwander-Tetri B.A., Brunt E.M., Guzelian PS, and Evans R.M. (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439. (Pubitemid 30625566)
45. Yanagimoto T., Itoh S., Sawada M, and Kamataki T. (1997) Mouse cytochrome P450 (Cyp3a11): Predominant expression in liver and capacity to activate aflatoxin B1. Arch Biochem Biophys 340:215-218. (Pubitemid 27200528)
46. Yu A.M., Fukamachi K., Krausz K.W., Cheung C, and Gonzalez F.J. (2005) Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 146:2911-2919. (Pubitemid 41002798)
47. Zhang J., Huang W., Chua S.S., Wei P, and Moore D.D. (2002) Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298:422-424. (Pubitemid 35176352)